SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-030934
Filing Date
2023-06-30
Accepted
2023-06-30 10:22:12
Documents
13
Period of Report
2023-06-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20230630.htm   iXBRL 8-K 63781
2 EX-99.1 cyt-ex99_1.htm EX-99.1 24822
  Complete submission text file 0000950170-23-030934.txt   226337

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20230630_pre.xml EX-101.PRE 11412
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20230630.xsd EX-101.SCH 2443
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20230630_lab.xml EX-101.LAB 13895
7 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20230630_htm.xml XML 5037
Mailing Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 231059988
SIC: 2834 Pharmaceutical Preparations